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Abstract
Introduction: Literature controversies exist regarding the prognostic value of VHL 
mutations. The objective was to compare paraffin-embedded and frozen section specimens for 
VHL mutations detection and to evaluate the reliability of DNA analysis in formalin-fixed 
tissues.
Methods: 76 patients with clear cell RCCs previously assessed for VHL status from frozen 
samples were included. 73 tumour samples were known to be mutated for VHL. DNA was 
extracted and an electrophoresis was performed to determine DNA quality. The whole coding 
sequence was synthesized by double PCR amplification followed by sequencing. Sequencing 
results were compared to those previously determined from frozen samples.
Results: DNA could be extracted from the 76 paraffin samples. DNA quality was highly 
degraded and significantly less amplified by PCR in 34.2%, resulting in no sequence available 
for analysis in 57.7% and discordance with frozen samples in 42.3% of the cases respectively. 
VHL mutations were found in 52.1% of the whole paraffin samples whereas 98% were 
mutated. 72% could be sequenced, resulting in 69.1% of VHL mutations in this subset. Only 
half of observed mutations were fully consistent with frozen analysis in the 3 exons. 
Neomutations were found in 10.5% and 28.9% of known mutations in frozen samples were 
not detected in paraffin blocks. Only DNA quality significantly influenced PCR amplification 
and sequencing.
Conclusion: Tumoral DNA extraction and VHL mutation analysis can be performed from 
FFPE tissue in RCC. But mutations identified tissues are not strictly concordant with those 
from frozen analysis and therefore results obtained from FFPE samples should be interpreted 
with care.
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Introduction
Renal cell carcinoma (RCC) is one of the most lethal urological cancers. About 30% 
of patients do have metastases at presentation and 40% will subsequently develop distant 
tumor spreading1. Obviously, the occurrence of solid tumors results from accumulation of 
genetic changes and von Hippel-Lindau (VHL) inactivation is the most frequent genetic event 
in sporadic RCC2.
The VHL gene is located on chromosomal region 3p25-26, and is composed of 3 
exons3. Inactivation of the VHL tumor suppressor gene plays an important role in hereditary 
and sporadic clear cell RCC4. The main consequence of VHL gene  inactivation is over 
expression of a transcription factor called hypoxia inducible factor (HIF), that activates genes 
involved in chronic or acute hypoxia, such as vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF), or transforming growth factor (TGF)5. Significant 
progress in understanding molecular pathways involved in RCC recently led to the 
development of novel therapies targeting VHL downstream products, with unprecedented 
response rates, improved progression free and overall survival in metastatic RCC6. However, 
there is an increasing need for identifying new predictors for drug efficacy in the context of 
anti-angiogenic treatment in metastatic disease. Because VHL gene alteration is usually 
considered as an early event in RCC carcinogenesis, its determination could also be of interest 
for predicting outcome in localized disease. 
Controversies exist in the literature regarding relationship between VHL alterations 
and renal cancer aggressiveness. Some authors consider VHL mutations as carrying out a 
favourable prognosis7,8, while others found no association or even demonstrate a poorer VHL 
altered associated prognostic 9-11. These studies are based on heterogeneous populations and 
methods , reporting mutation rates ranging from 29% in paraffin-embedded tissues12 to 71% 
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in frozen specimens13. There is no study available so far comparing the performance of 
determining VHL status in sporadic RCC in frozen and in formalin-fixed paraffin-embedded 
(FFPE) tissue respectively. 
Since 2003, we prospectively determined VHL status in clear cell RCC tumors 
operated at our institution based on frozen samples analysis14. We therefore decided in the 
present study to compare paraffin-embedded and frozen section specimens for VHL mutations 
detection and furthermore to evaluate the reliability of DNA analysis in FFPE tissues. 
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Materials and methods
Data collection
This retrospective study included 76 patients operated for a sporadic clear cell RCC at the 
department of Urology of the Rennes University Hospital between 2002 and 2005, and for 
whom VHL mutations had been characterised prospectively on frozen samples14. Among these 
patients, 3 were free of mutation and considered as a control group. The study protocol was 
approved by the institutional ethics committee and informed consent for participating in this 
study was obtained in each case. Clinical parameters such as age, sex and type of surgery and 
information on DNA concentration and quality, general aspect of the paraffin-embedded 
block, proportion of tumor present on the block, length of formalin fixation, and type of 
mutation were collected in all cases.
Pathological  analysis
FFPE sections were stained with hematoxylin and eosin-safran for light microscopy. The 
slides were reviewed by one pathologist (NRL). Only conventional clear cell carcinomas were 
considered for analysis. Macroscopic and histologic parameters which were analysed included 
tumor size (cm) and nuclear Fuhrman grade. Tumor stage was defined according to the 2002 
TNM classification15.
DNA extraction
For each patient, the best PFFE block was selected by a single uropathologist (NRL) using the 
following criteria: predominance of tumor present on the block, tumor homogeneity, zones of 
high Fuhrman grade, absence of tumor necrosis, cystic zone or normal renal tissue.
Genomic DNA was extracted from eight 10 µm-slices from each sample and prepared as 
follow: paraffin was removed with xylene according to standard procedures, followed by a 
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proteic digestion with a proteinase K solution. DNA was then extracted using a specific kit 
and according to the manufacturer’s instructions (RecoverAll™ Total Nucleic Acid Isolation 
– cat 1975, AMBION®). The DNA concentration was measured at 260 nm.
DNA quality was determined by electrophoresis on a 1% agarose gel running with 0.5X TBE 
buffer at room temperature for 30 min at 100V. Each sample was compared to a ladder 
(Smartladder®, Eurogentec) and classified according to their smear as “highly degraded” if 
only small DNA fragments were present, or “slightly degraded” if large DNA fragments were 
found (Figure 1).
VHL mutational analysis
DNA fragments encompassing the 3 exons of the VHL gene were amplified. In exon 1, the 
sequence located between codon 1 to 54 was not amplified because no mutation has ever been 
found either in our series, or in the literature. We used specific primers, as previously 
described for frozen samples analysis14,16. A double amplification was performed using 100 ng 
of the extracted DNA which was subjected to 35 cycles of PCR after an initial denaturation of 
9 min at 95°C including: denaturing during 1 min at 95°C, annealing during 45 s at 58°C for 
exon 1 and 2, and 45 s at 57°C for exon 3, then extension during 45 s at 72°C.
Exon amplification was performed in 30µl containing: 500 mM KCl, 10 mM Tris-HCl (pH 
8.3), 1.5 mM MgCl2, 250 µM dNTPs, 10 pmol of each primer and 1 U AmpliTaq Gold® 
polymerase (Applied Biosystems). For exon 1 and 3, 3% DMSO was used because of their 
high content of guanine and cytosine. Electrophoresis was carried out on a 2% agarose gel in 
the same conditions than previously described to control the success of the amplification 
procedure.
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For sequence analysis, purification of the amplified products was performed with ExoSAP-
IT® (USB), according to the manufacturer’s instructions, to filter out small fragments. 
Amplification products detected on SSCP were purified using chromatography columns 
(Sephadex G50®, Amershan Bioscience). Sequencing used BigDye® Terminator mix V3. 1 
(Applied Biosystems) and samples were re-amplified during 30 cycles of PCR: 30 s at 96°C, 
15 s at 55°C at Tm, and 4 min at 60°C. Finally, the sequenced products were subjected to 
automated sequence analysis on an ABI PRISM® 3130 Genetic Analyser (Applied 
Biosystems), and compared with the VHL sequence accession number AF0102383.
Mutations were identified by visual aspect of sequences by 2 persons and called when 
unequivocally present on the sense and/or the antisense strand.
Statistical analyses
χ² analysis was used for assessing differences in clinicopathologic parameters distribution. 
Associations between variables were assessed by χ² analysis. All analyses were conducted 
with SPSS 13.0.1 software (SPSS Inc, Chicago, Il, USA), and p-value significance was fixed 
at 0.05.
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Results
Patients and tumors 
The population was composed of 46 men (60.5%) and 30 women (39.5%) with a median age 
of 65 years [40-83]. Tumors were organ confined in 46 cases (60.5%). Median tumor size was 
6.7 cm [1.5 – 18]. Nodal invasion and distant metastases were present in 5 (6.6%) and 19 
(25%) cases, respectively. Tumors were of high nuclear Furhman grade (grade 3 and 4) in 47 
cases (61.8%). At the end of follow-up 15 patients (19.7%) died from renal cancer (Table 1).
DNA characteristics
Median DNA concentration was 222 ng/µl [30 – 693]. Even though the best quality block was 
selected by a single pathologist in all cases, imperfections potentially influencing DNA 
extraction were noticed in half of the FFPE blocks: presence of necrosis, fat, oedema and 
fibrosis, haemorrhagic or cystic zones. Most of the samples were formalin-fixed during 24h 
(52.6%). DNA was considered as highly degraded on electrophoresis in 26 cases (34.2%) 
(Table 2). In this setting, no sequencing was possible in 57.7% of the cases (n= 15), and in 11 
cases (42.3%)  a sequencing discordance was found compared to  frozen samples analysis 
(“extinction” of the mutation, other mutation, or multiple mutations present on the same exon 
or in different exons). Among the 76 samples, 72% could be sequenced, resulting in 69.1% 
VHL mutation rate in this subset. Multiple mutations were found in 5 specimens. In frozen 
analysis, 98% of the specimens were VHL mutated while a 52% mutation rate was identified 
in FFPE specimens. Among paraffin-embedded identified mutations, only 40.8% were fully 
consistent with frozen analysis in the 3 exons. Mutations not pre-existing in frozen samples 
were found in 10.5%, whereas 28.9% disappeared. 
Regarding DNA quality and sequencing analysis, 26 samples presented a “highly degraded” 
DNA. Only 11 samples have been sequenced (42.3%). In this subset, no mutations was found 
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in 2 cases, mutations not pre-existing in frozen samples were found in 2 cases, and mutations 
had disappeared in 4 cases. Nevertheless, no mutations was fully consistent with frozen 
samples.
In the 50 “slightly degraded” DNA subgroup sample, the 3 exons of the VHL gene have been 
sequenced for 44 samples (88%). Thirty (68.2%) were strictly consistent with frozen samples. 
Mutations not pre-existing in frozen samples were found in 4 cases, and mutations had 
disappeared in 2 cases.
Parameters influencing sequencing analysis
We therefore tried to identify parameters influencing PCR amplification and sequencing 
analysis in FFPE tissue (Tables 3 & 4). Only quality of extracted DNA appeared as a 
statistically significant parameter (p= 0.0001). DNA concentration, presence of more than 
70% of tumor on the block, imperfections on the block, duration of formalin-fixation or 
nuclear Furhman grade did not influence significantly sequencing analysis and occurrence of 
discordance. 
Similarly, we tried to identify parameters influencing quality of extracted DNA. Neither 
duration of formalin-fixation, imperfection on the block, anteriority of the sample, nor 
percentage of tumor influenced the quality of extracted DNA.
For making sure that such discordances were not due to block selection or presence of 
different mutated clones, we identified 10 samples with highly degraded DNA for which PCR 
amplification or sequencing analyses had not been possible, or where new mutations had 
appeared or disappeared during sequencing analysis. We subsequently repeated analysis in 
both new matched paraffin blocks and in frozen specimens. The same mutation was always 
identified in frozen specimen. In FFPE tissues, PCR amplification rates were comparable but 
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70% could not be sequenced as compared with 30% in initial samples. Only one result was 
retrieved within the 2 subsets: no mutation found whereas a mutation was identified in frozen 
analysis. In 2 cases, the mutation was not found whereas it had been initially identified.
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Discussion
VHL is considered as an early “gatekeeper” tumor suppressor gene, involved in cell 
cycle regulation, regulation of hypoxia inducible genes and proper fibronectin assembly in 
extracellular matrix2. It is presumed that further genetic alterations are needed for progression 
of preneoplastic lesions. Nevertheless, restoration of pVHL function in VHL-deficient renal 
carcinoma cells can suppress tumor growth both in vivo and in vitro17. However, in 10 to 20% 
sporadic ccRCCs, no alteration in the VHL alleles is detected, suggesting that other genes or 
pathways are involved in renal carcinogenesis18.
Gene abnormalities in hereditary Von Hippel-Lindau disease have been extensively analyzed. 
However few studies have focused on VHL alterations in sporadic ccRCC. These studies have 
been performed on frozen section tissues or on paraffin-embedded material and conflicting 
results have been reported. For example, 42 to 71% mutation rates have been described in 
frozen samples 7,9,13,19, while results seem to be inferior in FFPE tissues ranging from 20 to 
61%10,12,20,21. Currently, frozen section tissue is considered as the benchmark for DNA 
analysis22. Therefore, the objective of our study was to analyze the reliability of paraffin 
derived technique, compared to results obtained from frozen samples in matched specimens. 
Indeed, no study had previously addressed the accuracy of VHL gene analysis on FFPE 
material compared to frozen tissue even though the issue of predicting anti-angiogenic drug 
response through VHL gene analysis has gained a recent interest20,23.
Overall, in terms of VHL mutation location our results are consistent with the current 
literature (Table 5). Similarly to us, the majority of the studies reported exon 1 as being the 
predominant mutation site. A group identified exon 2 as the more frequent mutation site but 
the methodology used in this small series is subject to criticisms since reverse sequencing was 
performed only when any abnormality was detected24. Only 22% VHL mutations were 
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identified on frozen section tissue, by amplifying and sequencing only one DNA strand. 
Another group reported VHL mutation predominance in exon 3 through a limited series of 67 
tumors, and including only 24 ccRCCs25.
Our main finding was that out of the VHL mutated tumor population, only 52.1% mutations 
remained in FFPE tissue. New mutations not identified in frozen samples were found in 
10.5%, whereas 28.9% disappeared. In other words, only half of the true VHL abnormalities 
were identified when using FFPE tissue. Furthermore, only half of these mutations were 
strictly concordant within the 3 exons. 
When looking more accurately at the published data issued from the 2 types of tissue 
analyses, it appears that many discrepancies exist. First, similarly to what we obtained in our 
frozen series14, no mutation has ever been identified before codon 54 in frozen samples9,13,19,26. 
This region is known to interact with fibronectin and has been recently described as an 
important mediator for tumor invasion27. However, in FFPE tissues, similarly to the present 
series, many authors reported mutations in this region9,10,21,25. Interestingly, as others9,10,21, we 
found multiples mutations in some specimens, whereas it has never been described in any 
frozen series. Silent mutations have also been identified in FFPE samples in 11 to 13% of the 
cases11,12,21, whereas it has never been noticed in frozen samples. It is likely that these 
uncommon mutations have been created by the technique. These artifacts can be ascribed to 
postmortem deamination of cytosine and adenine, resulting in uracil or hypoxanthine residues 
respectively28. Several authors have described this phenomenon in different tissues 29. 
Williams et al reported up to 1 mutation artifact per 500 bases recorded30. It could also explain 
why some investigators found VHL mutations in papillary 21, undifferentiated or chromophobe 
carcinomas 11,25, and even in benign tumors like oncocytomas 11, while VHL abnormalities are 
highly specific for clear cell histological subtype 31. No study on frozen section tissues has 
ever identified VHL mutations in non clear cell RCC. Finally, the high percentage of errors 
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along with the observation of mutational heterogeneity raises the question whether paraffin 
material is suitable for VHL analysis. Both from our study and from a comprehensive analysis 
of the literature, it appears that paraffin derived technique is inferior to frozen analysis for 
VHL mutation analysis, resulting in quantitative and qualitative quality losses. In a 
retrospective study of brain tissue, Ferrer et al. analyzed the effects of formalin fixation and 
time storage on DNA preservation, and compared with frozen specimens 32. Acceptable 
results were obtained if DNA extraction was performed after a short time of fixation. 
Suboptimal and bad results (degraded DNA not allowing sequence analysis) occurred in 
FFPE tissues stored longer than 6 months. Moreover, the chance to obtain positive results was 
almost null in tissues that have been stored for years. Similar results were obtained with 
colorectal tissues. Though different artifacts have been used to optimize DNA extraction 
performance like higher-temperature heating under an alkaline condition 33 or longer 
rehydratation step during DNA extraction 34. All this data taken together strongly suggests that 
paraffin derived technique should not be considered as a standard for VHL gene analysis 
whether this evaluation should become important for predicting outcome following RCC 
treatment.
Beyond VHL gene analysis issues, this study suggests that results for DNA extraction 
and sequencing analysis from paraffin materials are less reliable than those taken from frozen 
samples. Therefore, caution is required when analyzing results of series using this material. 
However, when frozen tissue is not available, a very stringent selection of paraffin blocks 
with limited necrosis, fat, oedema, fibrosis, cystic or hemorrhagic zones is required. 
Additionally, selection of a homogeneous tumoral zone, exhibiting high nuclear grade and 
without any normal renal tissue is also of utmost importance. Ultimately, quality of the 
extracted DNA appears to be the major criterion for limiting errors associated with FFPE 
tissue analysis.
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Conclusion
Tumoral DNA extraction and VHL mutation analysis can be performed from FFPE 
tissue in RCC. But mutations identified from FFPE tissues are not strictly concordant with 
those from frozen analysis. If available, frozen tissue analysis should be considered the gold 
standard. Otherwise paraffin-embedded tissue remains a great opportunity for DNA analysis 
in long term-follow-up series. Our study opens the gate for a critical analysis of the literature 
in this field.
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Variables n (%)
Median age 65 years old [40-83]
Sex ratio (M/F) 46/30 (60.5%)
T stage :
T1
T2
T3
T4
33 (43.4%)
13 (17.1%)
27 (35.5%)
4 (3.9%)
N stage:
N0
N1-2
71 (93.4%)
5 (6.6%)
M stage :
M0
M1
57 (75%)
19 (25%)
Furhman grade:
Grade 1
Grade 2
Grade 3
Grade 4
0 (0%)
29 (38.2%)
34 (44.7%)
13 (17.1%)
Median tumor size (cm) 6.7 cm [1.5-18]
Type of surgery 66 Total nephrectomies (86.8%)10 Nephron sparing surgeries (13.2%)
Death 19 (25%)
Death from cancer 15 (19.7%)
Table 1: General characteristics of the studied population (n= 76).
Variables n (%)
Median DNA concentration 222 ng/µl [30 – 693]
Median tumor % on the FFPE block 70% [30-100]
Samples sequenced in the 3 exons 55/76 (72.4%)
DNA quality on the smear:
- Highly degraded
- slightly degraded
26/76 (34.2%)
50/76 (65.8%)
General aspect of the  FFPE block   : 
- Excellent quality
- Necrosis
- Fat
- Œdemea
- Hemorragia
- Fibrosis
- Cystic
38/76 (50%)
25/76 (32.9%)
5/76 (6.6%)
1/76 (1.3%)
1/76 (1.3%)
3/76 (3.9%)
3/76 (3.9%)
Formalin-fixed duration:
24h
48h
72h
96h
40/76 (52.6%)
13/76 (17.8%)
20/76 (26.3%)
3/76 (4.1%)
Mutations identified in FFPE tissue 38/73 (52%)
Mutations errors 29/76 (38.2%)
Table 2: Biological and pathological characteristics of the 76 samples.
No sequence available
(n= 21)
Sequence available 
(n= 55) p
Mean DNA 
concentration (ng/µl) 206.1 260.9 0.08
≥70% of tumor present 
on the block 16/21 (76.2%) 35/55 (63.6%) 0.8
Presence of 
imperfections on the 
block
12/21 (57.1%) 27/55 (49.1%) 0.6
Time of formalin 
fixation ≤24h 14/21 (66.7%) 26/55 (47.3%) 0.2
SMEAR  
DNA highly degraded 15/21 (71.4%) 11/55 (20%) 0.0001
Furhman grade :
Grade 2
Grade 3
Grade 4
5/21 (23.8%)
10/21 (47.6%)
6/21 (28.6%)
24/55 (43.6%)
24/55 (43.6%)
7/55 (12.7%)
0.2
Table 3: Parameters influencing sequencing analysis.
Discordance (n= 28) Samples fully consistent with frozen samples (n= 30) p
Median DNA 
concentration (ng/µl) 266.1 248.1 0.5
≥70% of tumor present 
on the block 20/28 (71.4%) 17/30 (56.7%) 0.4
Presence of 
imperfections on the 
block
13/28 (46.4%) 17/30 (56.7%) 0.5
Time of formalin 
fixation ≤24h 16/28 (57.1%) 14/30 (46.7%) 0.2
SMEAR  
DNA highly degraded 14/28 (50%) 0/30 (0%) 0.0001
Furhman grade :
Grade 2
Grade 3
Grade 4
10/28 (35.7%)
14/28 (50%)
4/28 (14.3%)
14/30 (46.7%)
11/30 (36.7%)
5/30 (16.7%)
0.8
Table 4: Parameters influencing sequencing errors.
ccRCC (n) Mutation rate
Predominant 
mutation site
Predominant type of 
mutation
Ma et al (2001) 81 54% Exon 1 FRAMESHIFT
Schraml et al (2002) 113 34% Exon 1 FRAMESHIFT
Barnabas et al (2002) 24 50% Exon 3 FRAMESHIFT
Kim et al (2005) 56 20% Exon 1 MISSENSE
Van Houwelingen et al 
(2005) 187 61% Exon 1 FRAMESHIFT
Rini et al (2006) 43 58% Exon 1 FRAMESHIFT
Table 5: VHL mutational analysis in FFPE histologic specimens, results from the 
literature.
Figure 1: DNA quality determined by electrophoresis on a 1% agarose gel. Each sample 
was compared to a ladder (1) and classified according to their smear as “highly 
degraded” if only small DNA fragments were present (3), or “slightly degraded” if large 
DNA fragments were found (4). N°2 represents a frozen sample.
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